Il-6和UGT1A1的变异可能与心力衰竭患者的富洛塞米德耐药性有关
G Koprululu Kucuk1,2, A I Guney3, M Sunbul4
1Faculty of Medicine, Department of Medical Biology, Yeditepe University, Istanbul, Turkey.
IUBMB life
|June 1, 2023
概括
在心力衰竭患者中,UGT1A1和IL-6的遗传变异会影响富洛塞米德耐药性. 这项研究确定了与药物反应不良相关的特定基因突变,为个性化心力衰竭治疗铺平了道路.
科学领域:
- 药物遗传学 药物遗传学
- 心脏病学 心脏病学
- 分子生物学分子生物学
背景情况:
- 富洛塞米德是心力衰竭 (HF) 管理的关键利尿剂.
- 当药物在某些HF患者中效率低下时,罗塞米德耐药性发生.
- 了解遗传因素可以优化HF治疗.
研究的目的:
- 调查UDP-glucuronosyltransferase 1 (UGT1A1) 与IL-6 (IL-6) 基因变异之间的关联,以及HF患者的复胺耐药性.
- 为了识别特定的基因标记,预测furosemide反应.
- 探索新型遗传变异对蛋白质结构的影响.
主要方法:
- 研究包括60名HF患者和30名健康对照.
- 患者被分为富洛塞米德耐药 (不响应者) 和非耐药 (响应者) 组.
- 通过直接测序分析UGT1A1变异;通过RT-PCR分析IL-6 (rs1800795,rs1800796) 变异.
- 在基分析中评估了新突变对蛋白质结构的影响.
主要成果:
- 检测到11种UGT1A1变异,其中9种是新型,8种导致氨基酸变化.
- 与对照组相比,HF患者的IL-6 rs1800796突变显著高于对照组 (p=0.027) 和非响应者 (p=0.043).
- 在患者中,IL-6 rs1800795的C等位基因较高 (p=0.032),而UGT1A1 55T插入在非响应者中较高 (p=0.017).
- 在分析中,发现了两种有害的变异和六种可能有害的变异.
结论:
- 特定的UGT1A1和IL-6基因变异与心力衰竭中的富洛塞米德耐药性有关.
- 这些发现有助于理解HF治疗中的药物遗传因素.
- 这项研究支持为HF患者开发个性化治疗策略.
相关概念视频
01:22Heart Failure Drugs: Diuretics
430
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
430
01:11Renal Failure: Dose Adjustments
127
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
127
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
471
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
471
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16